| Autor: |
Imai, Hiroo, Komine, Keigo, Takahashi, Shin, Saijo, Ken, Okada, Yoshinari, Kobayashi, akihiro, Okita, akira, Chikamatsu, Sonoko, Kasahara, Yuki, Takahashi, Masahiro, Oishi, Takayuki, Shirota, Hidekazu, Takahashi, Masanobu, Shimodaira, Hideki, Ishioka, Chikashi |
| Předmět: |
|
| Zdroj: |
Chemotherapy (0009-3157); Aug2016, Vol. 61 Issue 5, p262-268, 7p |
| Abstrakt: |
Background: Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Methods: Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment. Results: A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively. Conclusions: There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
